A Phase 4 interventional study of Tramadol Hydrochloride 50mg and Celebrex 200mg in Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.
Among the 307 studies in Back Pain with a site in United States, this one is the 11th largest by enrollment of the 262 interventional ones that give a count, is one of 16 that started in 2006, is one of 30 in phase 4, and was the 19th registered.
728 studies on the registry are indexed under Back Pain; 109 are open to participants now.
Browse Back Pain studies →38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of Houston · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Northwestern University · Sites in United States, Thailand, Ukraine
University of Colorado, Denver · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 21–84
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 33 · Phase 4 30
First in 1997; this study’s year is marked. 16 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 754 is above the median of 70 across 593 interventional studies indexed under Back Pain.
Median enrollment 76 across the 262 interventional studies, 133 across the 44 observational. Of the 228 that completed or were terminated, 105 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 307 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Back Pain — fewer than ten, so there is no comparison to draw.
21 of the studies in Back Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT05052541Phase 3University of Colorado, DenverSafety and Efficacy of Oral Cannabis in Chronic Spine Pain | 2027-06 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 307 studies in Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6.
To compare the effects of treatment with celecoxib 200 mg BID and tramadol hydrochloride 50 mg QID on improvement in functionality and quality of life in subjects with chronic low back pain.
The record gives a start of Mar 2006 and a primary completion of Dec 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →